Notice of Results

RNS Number : 8568F

Tissue Regenix Group PLC

26 February 2018

 

Tissue Regenix Group plc

Notice of Results 

Leeds, 26 February 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces it will release its unaudited preliminary results for the year ended 31 December 2017 on Monday 19 March.

Further information regarding an analyst call will follow in due course. 

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Head of Communications	Tel: [phone]
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  [phone]
FTI Consulting  Brett Pollard / Mo Noonan/ Rob Winder	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

NORDMGZZZKZGRZZ